中国骨质疏松杂志
中國骨質疏鬆雜誌
중국골질소송잡지
CHINESE JOURNAL OF OSTEOPOROSIS
2015年
4期
476-481
,共6页
甲状旁腺素%骨质疏松症%骨折%骨密度%骨强度
甲狀徬腺素%骨質疏鬆癥%骨摺%骨密度%骨彊度
갑상방선소%골질소송증%골절%골밀도%골강도
Parathyroid hormone%Osteoporosis%Fracture%Bone mineral density%Bone strength
骨质疏松症( OSTEOPOROSIS, OP)是一种以骨量低下、骨微结构损坏而导致骨脆性增加、易发生骨折为特征的全身性骨病。骨质疏松症所致的骨折严重影响患者的健康和生活质量,并对社会经济造成沉重的负担。目前骨质疏松症的治疗手段主要是以双膦酸盐类为主的抗骨吸收类药物。这类药物抑制骨吸收,但无法新生成骨组织。以重组人甲状旁腺素(1-34)[PTH(1-34)]为代表的促骨形成类药物作用于成骨细胞,通过刺激骨形成发挥作用,为治疗骨质疏松症提供了新的选择。多项临床研究证明PTH(1-34)可增加骨密度并改善骨结构,长期应用可降低骨质疏松症患者椎体和非椎体骨折发生率。 PTH (1-34)已在中国获批用于治疗有骨折高发风险的绝经后妇女骨质疏松症。骨质疏松症不仅增加了患者发生骨折的风险,也使得骨折愈合更加困难。由于PTH(1-34)特殊的成骨作用机制,近年来其在治疗骨折不愈合和脊柱融合等骨科领域的应用也日益受到重视,并且已经有一些成功的个案报道。本文回顾了近年来国内外关于PTH(1-34)在骨质疏松症和骨科领域的临床研究的进展,以期为临床实践提供参考。
骨質疏鬆癥( OSTEOPOROSIS, OP)是一種以骨量低下、骨微結構損壞而導緻骨脆性增加、易髮生骨摺為特徵的全身性骨病。骨質疏鬆癥所緻的骨摺嚴重影響患者的健康和生活質量,併對社會經濟造成沉重的負擔。目前骨質疏鬆癥的治療手段主要是以雙膦痠鹽類為主的抗骨吸收類藥物。這類藥物抑製骨吸收,但無法新生成骨組織。以重組人甲狀徬腺素(1-34)[PTH(1-34)]為代錶的促骨形成類藥物作用于成骨細胞,通過刺激骨形成髮揮作用,為治療骨質疏鬆癥提供瞭新的選擇。多項臨床研究證明PTH(1-34)可增加骨密度併改善骨結構,長期應用可降低骨質疏鬆癥患者椎體和非椎體骨摺髮生率。 PTH (1-34)已在中國穫批用于治療有骨摺高髮風險的絕經後婦女骨質疏鬆癥。骨質疏鬆癥不僅增加瞭患者髮生骨摺的風險,也使得骨摺愈閤更加睏難。由于PTH(1-34)特殊的成骨作用機製,近年來其在治療骨摺不愈閤和脊柱融閤等骨科領域的應用也日益受到重視,併且已經有一些成功的箇案報道。本文迴顧瞭近年來國內外關于PTH(1-34)在骨質疏鬆癥和骨科領域的臨床研究的進展,以期為臨床實踐提供參攷。
골질소송증( OSTEOPOROSIS, OP)시일충이골량저하、골미결구손배이도치골취성증가、역발생골절위특정적전신성골병。골질소송증소치적골절엄중영향환자적건강화생활질량,병대사회경제조성침중적부담。목전골질소송증적치료수단주요시이쌍련산염류위주적항골흡수류약물。저류약물억제골흡수,단무법신생성골조직。이중조인갑상방선소(1-34)[PTH(1-34)]위대표적촉골형성류약물작용우성골세포,통과자격골형성발휘작용,위치료골질소송증제공료신적선택。다항림상연구증명PTH(1-34)가증가골밀도병개선골결구,장기응용가강저골질소송증환자추체화비추체골절발생솔。 PTH (1-34)이재중국획비용우치료유골절고발풍험적절경후부녀골질소송증。골질소송증불부증가료환자발생골절적풍험,야사득골절유합경가곤난。유우PTH(1-34)특수적성골작용궤제,근년래기재치료골절불유합화척주융합등골과영역적응용야일익수도중시,병차이경유일사성공적개안보도。본문회고료근년래국내외관우PTH(1-34)재골질소송증화골과영역적림상연구적진전,이기위림상실천제공삼고。
Osteoporosis is a disease characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to an enhanced bone fragility and a consequent increase in fracture risk.The fracture caused by osteoporosis seriously impacts on the health and life quality of patients and causes heavy burden to social economy.Nowadays, the major therapy for osteoporosis is antiresorptive treatment, of which bisphosphonates are representative.Bisphosphonates inhibit bone resorption.However, they can not increase bone formation.Anabolic therapies that are represented by recombinant human parathyroid hormone (1-34) ( PTH[1-34]) act on osteoblasts and stimulate bone formation, and thus provide a different choice for osteoporosis treatment.Multiple clinical studies have shown that teriparatide is able to increase bone mineral density and to improve bone structure, and its long-term application can reduce the incidence of vertebral and non-vertebral fracture in patients with osteoporosis.PTH ( 1-34 ) has been approved in China to treat postmenopausal women with osteoporosis at high risk for fracture.Osteoporosis not only increases the risk of fractures but also makes fracture healing more difficult.Given the specific mechanism of action of PTH ( 1-34 ) on bone formation, increased attention has also been paid to its application in the orthopedics field, such as fracture healing and spinal fusion, and there have been some case reports in this field.This review summarizes the recent progresses in clinical studies of PTH (1-34) in osteoporosis and orthopedics field, which may be used as a reference for clinical practice.